767 related articles for article (PubMed ID: 21937658)
1. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
Bolles M; Deming D; Long K; Agnihothram S; Whitmore A; Ferris M; Funkhouser W; Gralinski L; Totura A; Heise M; Baric RS
J Virol; 2011 Dec; 85(23):12201-15. PubMed ID: 21937658
[TBL] [Abstract][Full Text] [Related]
2. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
[TBL] [Abstract][Full Text] [Related]
3. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.
Deming D; Sheahan T; Heise M; Yount B; Davis N; Sims A; Suthar M; Harkema J; Whitmore A; Pickles R; West A; Donaldson E; Curtis K; Johnston R; Baric R
PLoS Med; 2006 Dec; 3(12):e525. PubMed ID: 17194199
[TBL] [Abstract][Full Text] [Related]
4. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
[TBL] [Abstract][Full Text] [Related]
5. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
[TBL] [Abstract][Full Text] [Related]
6. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
[TBL] [Abstract][Full Text] [Related]
7. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
[TBL] [Abstract][Full Text] [Related]
8. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
Sheahan T; Whitmore A; Long K; Ferris M; Rockx B; Funkhouser W; Donaldson E; Gralinski L; Collier M; Heise M; Davis N; Johnston R; Baric RS
J Virol; 2011 Jan; 85(1):217-30. PubMed ID: 20980507
[TBL] [Abstract][Full Text] [Related]
9. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
[TBL] [Abstract][Full Text] [Related]
10. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
[TBL] [Abstract][Full Text] [Related]
12. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
13. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Cavanagh D
Avian Pathol; 2003 Dec; 32(6):567-82. PubMed ID: 14676007
[TBL] [Abstract][Full Text] [Related]
14. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.
Regla-Nava JA; Nieto-Torres JL; Jimenez-Guardeño JM; Fernandez-Delgado R; Fett C; Castaño-Rodríguez C; Perlman S; Enjuanes L; DeDiego ML
J Virol; 2015 Apr; 89(7):3870-87. PubMed ID: 25609816
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
16. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.
See RH; Petric M; Lawrence DJ; Mok CPY; Rowe T; Zitzow LA; Karunakaran KP; Voss TG; Brunham RC; Gauldie J; Finlay BB; Roper RL
J Gen Virol; 2008 Sep; 89(Pt 9):2136-2146. PubMed ID: 18753223
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
18. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV.
Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M
J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225
[TBL] [Abstract][Full Text] [Related]
19. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
